1427-06-1

Basic information

• Product Name: 6-FLUORONICOTINIC ACID METHYL ESTER
• Synonyms: 6-FLUORONICOTINIC ACID METHYL ESTER;METHYL6-FLUORONICOTINATE;Methyl 6-fluoropyridine-3-carboxylate;3-Pyridinecarboxylic acid, 6-fluoro-, methyl ester;Methyl 6-fluoropyridine-3-carboxylate, 6-Fluoro-3-(methoxycarbonyl)pyridine;6-fluoro-3-Pyridinecarboxylic acid Methyl ester;6-Fluoro-3-(Methoxycarbonyl)pyridine
• CAS NO: 1427-06-1
• Molecular Formula: C₇H₆FNO₂
• Molecular Weight: 155.13
• Product Categories: Pyridine;pharmacetical;Pyridines;Boronic Acid;Picolinic acid series;NULL;Fluorine series;Imidazoles ,Homopiperidines
• Mol File: 1427-06-1.mol
• Article Data: 4

Chemical Properties

• Melting Point: 48-52 °C
• Boiling Point: 210.311 °C at 760 mmHg
• Flash Point: 99 °C
• Appearance: /Solid
• Density: 1.243 g/cm³
• Vapor Pressure: 0.194mmHg at 25°C
• Refractive Index: 1.491
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: -2.47±0.10(Predicted)
• CAS DataBase Reference: 6-FLUORONICOTINIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 6-FLUORONICOTINIC ACID METHYL ESTER(1427-06-1)
• EPA Substance Registry System: 6-FLUORONICOTINIC ACID METHYL ESTER(1427-06-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26-36/37/39-45
• WGK Germany: 3
• Hazardous Substances Data: 1427-06-1(Hazardous Substances Data)

Usage

General Description

6-Fluoronicotinic acid methyl ester is a chemical compound that belongs to the class of fluorinated organic compounds. It is derived from nicotinic acid and contains a methyl ester functional group. 6-FLUORONICOTINIC ACID METHYL ESTER has potential applications in the field of organic synthesis and pharmaceuticals. It is commonly used as a building block in the synthesis of various pharmaceutical ingredients and agrochemicals. It is also used as a precursor in the production of fluorinated derivatives of nicotinamide, which have been studied for their potential biological activities. Overall, 6-fluoronicotinic acid methyl ester is an important intermediate compound with versatile applications in chemical and pharmaceutical industries.

InChI:InChI=1/C7H6FNO2/c1-11-7(10)5-2-3-6(8)9-4-5/h2-4H,1H3

Upstream product

• 93-60-7 methyl 3-pyridinecarboxylate 
• 403-45-2 6-fluoronicotinic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 74-88-4 methyl iodide 

Downstream Products

• 1383801-14-6 (S)-methyl 6-[(3-methyl-1-{4-[5-(trifluoromethyl)pyridin-2-yl]phenyl}butyl)amino]nicotinate 
• 1383801-20-4 (S)-ethyl N-({6-[(3-methyl-1-{4-[5-(trifluoromethyl)pyridin-2-yl]phenyl}butyl)amino]pyridin-3-yl}carbonyl)-beta-alaninate 
• 1383802-61-6 3-[(6-{(S)-3-methyl-1-[2-(4-trifluoromethyl-phenyl)-pyrimidin-5-yl]-butylamino}-pyridine-3-carbonyl)-amino]-propionic acid ethyl ester 
• 1383802-59-2 6-{(S)-3-methyl-1-[2-(4-trifluoromethyl-phenyl)-pyrimidin-5-yl]-butylamino}-nicotinic acid 
• 1383801-45-3 (+/-)-6-[(cyclohexyl{2-[4-(trifluoromethyl)phenyl]pyrimidin-5-yl}methyl)amino]nicotinic acid 
• 1383802-45-6 3-[(6-{(S)-3-methyl-1-[2-(4-trifluoromethyl-phenyl)-pyrimidin-5-yl]-butylamino}-pyridine-3-carbonyl)-amino]-propionic acid 
• 1383801-02-2 (S)-N-({6-[(3-methyl-1-{4-[5-(trifluoromethyl)pyridin-2-yl]phenyl}butyl)amino]pyridin-3-yl}carbonyl)-β-alanine 
• 1383798-69-3 (+/-)-3-(6-(3-methyl-1-(4-(6-methylpyridin-3-yl)phenyl)butylamino)nicotinamido)propanoic acid 
• 1383802-56-9 6-{(S)-3-methyl-1-[2-(4-trifluoromethyl-phenyl)-pyrimidin-5-yl]-butylamino}-nicotinic acid methyl ester 
• 1383801-42-0 (+/-)-methyl 6-[(cyclohexyl{2-[4-(trifluoromethyl)phenyl]pyrimidin-5-yl}methyl)amino]nicotinate 
• 1383798-68-2 methyl 6-(1-(4-iodophenyl)-3-methylbutylamino)nicotinate 
• 4634-13-3 methyl 6-phenylnicotinate 

Relevant articles and documents

Glucagon Receptor Modulators

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

BENZOTRIAZEPINONE DERIVATIVES

The present invention is concerned with benzotriazepinone derivatives, their intermediates, uses thereof and processes for their production. In particular, the present invention relates to parathyroid hormone (PTH) and parathyroid hormone related protein (PTHrp) receptor ligands, (PTH-1 or PTH/PTHrp receptor ligands). The invention also relates to methods of preparing such ligands and to compounds which are useful as intermediates in such methods.